The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The Europe dry eye syndrome market is expected to exhibit a CAGR of X% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Dry eye syndrome, or keratoconjunctivitis sicca (KCS), is a medical disorder that occurs due to the lack of moisture or lubrication on the surface of the eye. It is a chronic ailment characterized by various symptoms, such as redness, discomfort, aching and burning sensations and photophobia. Dry eye syndrome is also caused due to multiple factors, such as allergies, laser surgeries, extensive computer usage, medication, menopause, deficiency of vitamin A and other autoimmune diseases. It can be treated through administering artificial tears, medications, lacrimal plugs and surgeries. Dry eye syndrome can be prevented by avoiding smoking and wearing wraparound sunglasses or other protective eyewear.
The growth in the Europe dry eye syndrome market can be attributed to the rising geriatric population prone to chronic eye-related diseases. Dry eye syndrome is also associated with various other medical conditions, such as Sjogren's syndrome, rheumatoid arthritis, lupus, scleroderma, sarcoidosis, thyroid disorders and diabetes, which is highly prevalent among elderly patients. In addition to this, sedentary lifestyles and a lack of physical activities of the masses are resulting in the increasing oxidative stress and reducing mucin expression in the eyes, which is also impacting the occurrence of dry eye syndrome. Consequently, patients and healthcare providers are widely adopting corticosteroids drugs for the effective treatment of dry eye syndrome. Corticosteroids are anti-inflammatory drugs that offer short-term efficacy and are prescribed for acute cases of dry eye diseases. Other factors, including significant improvements in the diagnostic technologies, along with rising healthcare expenditure capacities of the consumers and the increasing utilization of smartphones, laptops and television among the masses leading to prolonged and excessive screen time, are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the Europe dry eye syndrome market, along with forecasts at the country and regional level from 2022-2027. Our report has categorized the market based on disease type, drug type, product and distribution channel.
Breakup by Disease Type:
Breakup by Drug Type:
Breakup by Product:
Breakup by Distribution Channel:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
|Base Year of the Analysis||2021|
|Segment Coverage||Disease Type, Drug Type, Product, Distribution Channel, Country|
|Countries Covered||Germany, France, United Kingdom, Italy, Spain|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at